Pharmacokinetic interactions between antiretrovirals and immunosuppressants are critical elements in the management of HIV-infected patients who undergo kidney tranplantation (KTX) thus most transplant centres discontinue antiretrovirals until IS steady state is reached. The objective of the study was to assess the impact of an antiretroviral regimen based on enfuvirtide+raltegravir+NRTI on everolimus and cyclosporin pharmacokinetics in the early post-KTx period.
Raltegravir and enfuvirtide as a “bridge” antiretroviral therapy in kidney-tranplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study / S., Cocchi; D., Bonucchi; Pulizzi, Roberto; Ghiandai, Giulia; Mori, Giacomo; Americo, Claudio; Zona, Stefano; M., Codeluppi; Esposito, Roberto; Cappelli, Gianni; Guaraldi, Giovanni. - In: INFECTION. - ISSN 0300-8126. - STAMPA. - 38 Suppl.I:(2010), pp. 41-42. (Intervento presentato al convegno Italian Conference on AIDS and Retroviruses (ICAR) tenutosi a Brescia nel Jun 20-22 2010).
Raltegravir and enfuvirtide as a “bridge” antiretroviral therapy in kidney-tranplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study
PULIZZI, ROBERTO;GHIANDAI, GIULIA;MORI, Giacomo;AMERICO, Claudio;ZONA, Stefano;ESPOSITO, Roberto;CAPPELLI, Gianni;GUARALDI, Giovanni
2010
Abstract
Pharmacokinetic interactions between antiretrovirals and immunosuppressants are critical elements in the management of HIV-infected patients who undergo kidney tranplantation (KTX) thus most transplant centres discontinue antiretrovirals until IS steady state is reached. The objective of the study was to assess the impact of an antiretroviral regimen based on enfuvirtide+raltegravir+NRTI on everolimus and cyclosporin pharmacokinetics in the early post-KTx period.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
